Replimune Group, Inc.

For the period ended Dec 31, 2025. Filed Feb 3, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 3, 2026

REPL$22.26+3.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Amounts in thousands, except share and per share amounts)

	Three Months Ended December 31,		Nine Months Ended December 31,
	2025	2024	2025	2024
Operating expenses:
Research and development	$53,140	$48,004	$168,860	$135,472
Selling, general and administrative	18,728	18,015	77,721	46,827
Total operating expenses	71,868	66,019	246,581	182,299
Loss from operations	(71,868)	(66,019)	(246,581)	(182,299)
Other income (expense):
Research and development incentives	341	376	1,138	1,222
Investment income	2,846	5,137	11,256	15,243
Interest expense on finance lease liability	(514)	(528)	(1,553)	(1,594)
Interest expense on debt obligations	(1,466)	(1,450)	(4,429)	(4,314)
Other (expense) income, net	(580)	(3,281)	(865)	(850)
Total other income (expense), net	627	254	5,547	9,707
Loss before income taxes	$(71,241)	$(65,765)	$(241,034)	$(172,592)
Income tax (benefit) provision	(311)	$575	$(311)	$575
Net loss	$(70,930)	$(66,340)	$(240,723)	$(173,167)
Net loss per common share, basic and diluted	$(0.77)	$(0.79)	$(2.62)	$(2.25)
Weighted average common shares outstanding, basic and diluted	92,187,581	83,498,892	91,874,481	77,113,695

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.